Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data

Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data

Background Use of robotic systems for minimally invasive surgery has rapidly increased during the last decade. Understanding the causes of adverse events and their impact on patients in robot-assisted surgery will help improve systems and operational practices to avoid incidents in the future. Metho...

Full description

Bibliographic Details
Main Authors:	Alemzadeh, Homa (Author), Raman, Jaishankar (Author), Kalbarczyk, Zbigniew (Author), Iyer, Ravishankar K. (Author), Leveson, Nancy G (Contributor)
Other Authors:	Massachusetts Institute of Technology. Department of Aeronautics and Astronautics (Contributor)
Format:	Article
Language:	English
Published:	Public Library of Science, 2017-05-31T15:04:50Z.
Subjects:	Article
Online Access:	Get fulltext

Similar Items

Adverse Events in Robotic Surgery: A Retrospective Study of 14 Years of FDA Data.
by: Homa Alemzadeh, et al.
Published: (2016-01-01)

Systems-Theoretic Safety Assessment of Robotic Telesurgical Systems
by: Alemzadeh, Homa, et al.
Published: (2017)

Surgeon Training in Telerobotic Surgery via a Hardware-in-the-Loop Simulator
by: Xiao Li, et al.
Published: (2017-01-01)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
by: Dong-Hui Lao, et al.
Published: (2021-06-01)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.
by: Akiho Fukuda, et al.
Published: (2017-01-01)

A Systems Approach to Analyzing and Preventing Hospital Adverse Events
by: Samost, Aubrey, et al.
Published: (2018)

Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
by: Toshiyuki Sakaeda, et al.
Published: (2011-01-01)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020-09-01)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
by: Emanuel Raschi, et al.
Published: (2021-04-01)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
by: Long Meng, et al.
Published: (2021-02-01)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
by: Toshiyuki Sakaeda, Kaori Kadoyama, Yasushi Okuno
Published: (2011-01-01)

Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports
by: Judith U. Cope, et al.
Published: (2015-01-01)

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
by: Paul C. Macklis, et al.
Published: (2020-06-01)

Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
by: Kaori Kadoyama, Ikuya Miki, Takao Tamura, JB Brown, Toshiyuki Sakaeda, Yasushi Okuno
Published: (2012-01-01)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
by: Yusuke Kan, et al.
Published: (2021-05-01)

Adverse Events in Total Ankle Arthroplasty, Analysis of the FDA Medical and User Facility Device Experience Database
by: Karim Mahmoud MD, et al.
Published: (2019-10-01)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
by: Kavanagh KT, et al.
Published: (2019-07-01)

Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
by: Takao Tamura, Toshiyuki Sakaeda, Kaori Kadoyama, Yasushi Okuno
Published: (2012-01-01)

A retrospective cohort study of adverse events in patients undergoing orthopaedic surgery
by: Joel J. Gagnier, et al.
Published: (2017-05-01)

Adenotonsillectomy and postoperative respiratory adverse events: A retrospective study
by: Thomas B. Hamilton, et al.
Published: (2020-02-01)

Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics
by: Kirk E Evoy, et al.
Published: (2019-04-01)

Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System
by: Liwei Wang, et al.
Published: (2017-07-01)

OA12.01. Analysis of FDA mandated dietary supplement adverse event reports (AER) 2008-2009
by: Hardy M, et al.
Published: (2012-06-01)

A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
by: Keith B Hoffman, et al.
Published: (2012-01-01)

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
by: Sakaeda Toshiyuki, et al.
Published: (2011-10-01)

Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
by: Sandra de Bie, et al.
Published: (2015-01-01)

OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.
by: Ruwen Böhm, et al.
Published: (2016-01-01)

A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
by: Bin Wu, et al.
Published: (2021-05-01)

Safety of the newer disease-modifying agents for multiple sclerosis: disproportionality analysis in the FDA Adverse Events Reporting System database.
by: Vasiliki Nikolopoulou, et al.
Published: (2019-06-01)

Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
by: Toshiyuki Sakaeda, Kaori Kadoyama, Hiroaki Yabuuchi, Satoshi Niijima, Kyoko Seki, Yukinari Shiraishi, Yasushi Okuno
Published: (2011-01-01)

Aspirin- and Clopidogrel-associated Bleeding Complications: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
by: Takao Tamura, Toshiyuki Sakaeda, Kaori Kadoyama, Yasushi Okuno
Published: (2012-01-01)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
by: Yinghong Zhai, et al.
Published: (2021-09-01)

Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions
by: Kota Kurosaki, et al.
Published: (2021-06-01)

Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system
by: Mohamed Kadry Taher, et al.
Published: (2021-07-01)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Zhuo Ma, et al.
Published: (2021-07-01)

Applying systems thinking to analyze and learn from events
by: Leveson, Nancy G
Published: (2017)

Severe adverse events related to tattooing: An retrospective analysis of 11 years
by: Uwe Wollina
Published: (2012-01-01)

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
by: Santa Cirmi, et al.
Published: (2020-03-01)

Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database
by: Xiaojiang Tian, et al.
Published: (2021-06-01)

Detection of adverse events in surgery by record review
by: Olsen, Sisse Bjorn
Published: (2006)

Cannot write session to /tmp/vufind_sessions/sess_pprltun2o109b129803rrjtpio